世界のペット用癌治療薬市場：治療別、動物別、用途別、地域別 - 成長、動向、予測
Global Pet Cancer Therapeutics Market - Segmented by Therapy, Animal, Application, and Geography- Growth, Trends, and Forecast (2018 - 2023)
|発行||Mordor Intelligence LLP||商品コード||704736|
|出版日||ページ情報||英文 103 Pages
|世界のペット用癌治療薬市場：治療別、動物別、用途別、地域別 - 成長、動向、予測 Global Pet Cancer Therapeutics Market - Segmented by Therapy, Animal, Application, and Geography- Growth, Trends, and Forecast (2018 - 2023)|
|出版日: 2018年07月01日||ページ情報: 英文 103 Pages||
The pet cancer therapeutics market is expected to witness a CAGR of 9.1% over the forecast period. Pet cancer therapeutics refers to various therapeutic agents used to treat cancer in pet animals. The success rate of various treatments, preventing and curing neoplasia and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early recognition, diagnosis, and treatment. The growing prevalence of several types of cancers in cats and dogs, as well as increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. However, side effects associated with cancer treatment and high costs could adversely affect market growth.
High Prevalence of Cancer in Pets is Contributing to Market Growth
Rise in the prevalence of cancer in dogs and cats is expected to propel market growth, owing to the direct association of cancer prevalence with the need for proper pet cancer therapies. According to the Center for Cancer Research, National Cancer Institute, there are approximately 65 million dogs and 32 million cats in the United States. Out of these, around 6 million new cancer diagnoses are made in dogs and a similar number made in cats, each year. The American Veterinary Medical Association (AVMA) states that dogs develop cancer at almost the same rate as humans. However, there is less information about the rate of cancer in cats. Certain cancers, such as lymphoma, are more prevalent in cats, than in dogs. Cancers in pet animals are generally found in the skin, breast, bones, head and neck, abdomen, lymph system, and testicles. Leukemia is the type of cancer that has the highest prevalence in cats, whereas lymphoma and mammary gland cancer are the most common type of canine cancers.
In addition to the aforementioned factor, growing pet health awareness and rise in R&D initiatives regarding pet cancer management are expected to propel market growth over the forecast period.
Side Effects associated with Products and Treatments are Limiting Market Growth
The side effects associated with the drugs and other methods of treatment used for various types of canine and feline cancers are expected to restrain the growth of the market. The side effects that are most commonly experienced by dogs and cats receiving chemotherapy involve the gastrointestinal tract and the bone marrow. If the cell lining of the stomach and intestine are affected by chemotherapy, it could result in vomiting, diarrhea, and loss of appetite. Whereas the bone marrow is responsible for producing white blood cells (WBCs), and upon it being affected by chemotherapy, these WBC levels may decrease temporarily. Owing to the fact that WBCs are very important in regulating the immune system of the body, animals having less WBC count become susceptible to developing an infection. According to the American Animal Hospital Association (AAHA), certain breeds of dogs with continuously growing hair, such as poodles, Portuguese water dogs, Shih Tzu, and Maltese, are more likely to experience hair loss or alopecia. These breeds are generally expected to experience an overall thinning of the hair coat, rather than a total loss of hair.
As a result of these mild, as well as severe, side effects caused by drugs used for the treatment of pet cancers, the reluctance of pet owners to put their pet animals under medication is expected to restrain the pet cancer therapeutics market, thereby impeding market growth.
North America Dominates the Pet Cancer Therapeutics Market
North America is expected to dominate the pet cancer therapeutics market over the forecast period, owing to rising pet adoption, increasing per capita animal healthcare expenditure, and rise in prevalence of many diverse canine diseases. For example, The American Veterinary Medical Association (AVMA) states that approximately 25% of dogs are likely to develop neoplasia at some stage in their life. Almost 50% of dogs over the age of 10 develop cancer. In addition, growing awareness about canine health, among the pet owners, favorable and advanced infrastructure, helpful initiatives by the government, and rise in product innovation, such as new vaccine launches, are some other factors propelling the growth of the pet cancer therapeutics in North America.
Key Developments in the Market
Jan 2018 - Aratana Therapeutics was granted conditional approval for its canine osteosarcoma vaccine, live Listeria vector (AT-014), by the USDA's Center for Veterinary Biologics.
Major Players - ADVAVET INC. (OASMIA PHARMACEUTICALS AB), ARATANA THERAPEUTICS INC., ELIAS ANIMAL HEALTH (TVAX BIOMEDICAL), KARYOPHARM THERAPEUTICS INC., MERIAL (BOEHRINGER INGELHEIM GMBH), MORPHOGENESIS INC., RADIOLOGY ONCOLOGY SYSTEMS, REGENEUS LTD, VETDC INC., and ZOETIS among others.
Reasons to Purchase the Report
The current and future outlook of the global surgical microscopes market in the developed and emerging markets
Analysis of various perspectives of the market with the help of Porter's five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth during the forecast period
Identify the latest developments, market shares, and strategies employed by the major market players
3-month analyst support, along with the market estimate sheet (in Excel)
Customization of the report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
List Not Exhaustive